Trump announces trade deal with EU following months of negotiations
WILMINGTON, Del. - AstraZeneca (Market cap: $219.79B), a prominent player in the pharmaceuticals industry with an "GREAT" financial health rating according to InvestingPro, announced its triple-combination therapy, BREZTRI AEROSPHERE, met all primary endpoints in the Phase III KALOS and LOGOS trials for uncontrolled asthma, suggesting a significant improvement in lung function over dual-combination therapies. These results could potentially change the standard of care for asthma patients who remain uncontrolled despite current treatments.
The KALOS and LOGOS trials were designed to test the efficacy and safety of BREZTRI, which combines budesonide, glycopyrronium, and formoterol fumarate, in comparison with inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medications. The study included approximately 4,400 patients, with results indicating an improvement in lung function as measured by forced expiratory volume in one second (FEV1). The company’s strong gross profit margin of 82.44% and revenue growth of 15.48% over the last twelve months demonstrate its operational efficiency in bringing such innovations to market.
Asthma affects an estimated 262 million people globally, with nearly half of those treated with dual therapy still experiencing uncontrolled symptoms, which can significantly impact daily life and overall health. Professor Alberto Papi, the primary investigator, highlighted the importance of these findings for patients who continue to struggle with asthma control. For investors seeking deeper insights into AstraZeneca’s market position and growth potential, InvestingPro offers comprehensive analysis, including 8 additional key ProTips and detailed financial metrics.
Sharon Barr, Executive Vice President at AstraZeneca, expressed optimism about the potential of BREZTRI to improve patient outcomes, building on its established profile in treating chronic obstructive pulmonary disease (COPD).
No new safety or tolerability concerns were identified during the trials. The full results will be presented to regulatory authorities and at an upcoming medical meeting. Currently, BREZTRI is approved for COPD treatment in over 80 countries, including the US, EU, China, and Japan.
The information in this article is based on a press release statement from AstraZeneca.
In other recent news, AstraZeneca has reported several notable developments. The company received a recommendation from the European Union’s Committee for Medicinal Products for Human Use (CHMP) for its drug Calquence to treat chronic lymphocytic leukemia, based on positive results from the AMPLIFY Phase III trial. Meanwhile, AstraZeneca has decided to halt the CAPItello-280 Phase III trial of Truqap for metastatic castration-resistant prostate cancer after an interim analysis suggested the trial would not meet its primary endpoints. In a different strategic move, AstraZeneca has partnered with Tempus AI and Pathos AI to develop an AI-driven multimodal foundation model in oncology, with Tempus receiving $200 million for data licensing and model development. Additionally, AstraZeneca disclosed that Non-Executive Director Karen Knudsen purchased 1,400 American Depositary Shares, valued at over $100,000. These developments highlight AstraZeneca’s ongoing efforts in drug development and strategic partnerships to enhance patient care and drug discovery.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.